Skip to content

AcuCort as an Investment

Four reasons to invest in AcuCort

    1. Innovative product

      Zeqmelit® addresses a large patient need in acute and severe allergic reactions. The drug is a fast-soluble mouth film that is easy to carry with you and easy to put on the tongue, without the need for water.

    2. Large market

      About 20% of the world’s population suffers from allergic symptoms. The potential market for Zeqmelit™ is estimated to be worth more than USD 3 billion.

    3. Low development risk

      Zeqmelit® is fully developed and approved in Sweden, Denmark, Norway and Finland. The registration processes are ongoing in the rest of the EU.

    4. Competent and experienced team

      Company management and the Board of Directors have broad and deep experience of commercializing new drugs.